Concepedia

Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma

Charlotte Domblides, Karen Leroy, I. Monnet, Julien Mazières, Fabrice Barlési, V. Gounant, Simon Baldacci, B. Mennecier, Anne‐Claire Toffart, Clarisse Audigier-Valette,

Journal of Thoracic Oncology · 2020 · 136 citations · 16 references

DOIFull text

Open access

Concepts

References

16

<i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma

Ferdinandos Skoulidis, Michael E. Goldberg, Danielle Greenawalt et al. · Cancer Discovery · 2018 · 1.6K citations · Full text

, , +16

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Leora Horn, David R. Spigel, Everett E. Vokes et al. · Journal of Clinical Oncology · 2017 · 875 citations · Full text

, , +16

<i>TP53, STK11</i> , and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti–PD-1 in Lung Adenocarcinoma

Jérôme Biton, Audrey Mansuet‐Lupo, Nicolas Pécuchet et al. · Clinical Cancer Research · 2018 · 361 citations

, , +17

Efficacy of First-Line Chemotherapy in Patients with Advanced Lung Sarcomatoid Carcinoma

Thibault Vieira, Nicolas Girard, Mony Ung et al. · Journal of Thoracic Oncology · 2013 · 203 citations · Full text

, , +7

Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)

Vamsidhar Velcheti, David L. Rimm, Kurt A. Schalper · Journal of Thoracic Oncology · 2013 · 176 citations · Full text

, , +12